Cardiovascular Today—May 14, 2026

This week’s Cardiovascular update highlights clinical progress, device launches, care pathway innovation, research collaborations, and guideline-focused risk management.

In Today’s Newsletter

Dive deeper

💡 SCAI opens WONDER radiation study [1] [US • 12 May 2026]

https://cardiovascularbusiness.com/topics/clinical/interventional-cardiology/scai-seeks-female-interventional-cardiologists-radiation-risk-study
Context: WONDER targets younger female interventional cardiologists and fellows within five years of training.
Key point: SCAI is studying real-world cath lab radiation exposure using surveys and dosimeters.
Implication: May expand screening, initiation, and follow-up at scale.

🫀 CorFlow advances MOCA II MVO diagnostics [2] [US/EU • 11 May 2026]

https://cardiovascularnews.com/corflow-meets-performance-goals-in-moca-ii-trial/
Context: MOCA II phase 1 enrolled 19 STEMI patients across five US and three European sites.
Key point: CorFlow said PCoFI met safety and performance goals versus cardiac MRI for MVO diagnosis.
Implication: May influence prescriber choice and payer reviews pending full data.

🏠 Lasix ONYU reduces hospital days in SUBCUT HF II [3] [UK • 11 May 2026]

https://cardiovascularnews.com/subcut-hf-ii-trial-reports-fewer-hospital-days-for-hf-patients-treated-for-oedema-with-novel-therapy/
Context: SUBCUT HF II enrolled 172 heart failure patients across 20 NHS hospitals in the UK.
Key point: SQ Innovation reported at-home Lasix ONYU produced more days alive and out of hospital at 30 days.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

💧 Reprieve FASTR pilot supports guided decongestion [4] [US/EU • 11 May 2026]

https://cardiovascularnews.com/fastr-pilot-trial-results-published-in-jacc-heart-failure/ Context: FASTR studied Reprieve Therapy in acute decompensated heart failure with fluid overload.
Key point: Reprieve Cardiovascular said the pilot showed faster decongestion without increased safety events.
Implication: May influence prescriber choice and payer reviews pending full data.

🤖 Robocath completes first-in-human RA-PCI enrolment [5] [France • 11 May 2026]

https://cardiovascularnews.com/trial-of-first-in-human-trial-of-next-generation-robotic-pci-system-completes-enrolment/
Context: The first-in-human study enrolled 20 coronary artery disease patients at CCN in Saint-Denis, France.
Key point: Robocath completed enrolment for its next-generation robotic PCI system, with no safety concerns reported to date.
Implication: Signals pipeline investment and modality expansion.

⚡ J&J launches Shockwave C2 Aero coronary IVL catheter [6] [Global • 12 May 2026]

https://cardiovascularnews.com/jj-launches-shockwave-c2-aero-coronary-ivl-catheter-globally/
Context: Shockwave C2 Aero is a next-generation coronary IVL catheter for calcified coronary artery disease.
Key point: Johnson & Johnson launched the device globally, with availability in the US and Japan first.
Implication: Introduces competition that may affect pricing and formulary access.

💊 CardioPharma reviews polypill research applications [7] [US • 12 May 2026]

https://www.prnewswire.com/news-releases/cardiopharma-reviews-applications-to-explore-non-cardiovascular-benefits-of-cvd-polypill-302767133.html
Context: CardioPharma is reviewing applications for secondary analyses of existing CVD polypill datasets.
Key point: Proposed areas include dementia, cognitive decline, stroke, CKD, peripheral vascular disease, and ophthalmologic conditions.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

👶 AHA recommendations target postpartum cardiovascular care [8] [US • 12 May 2026]

https://www.hcplive.com/view/new-aha-recommendations-encourage-improving-postpartum-cardiovascular-care
Context: The AHA recommendations focus on postpartum systems, interdisciplinary care, policy, and risk monitoring.
Key point: AHA guidance encourages better identification and follow-up of cardiovascular risk after pregnancy.
Implication: May expand screening, initiation, and follow-up at scale.

Why it matters

Cath lab safety remains a workforce issue for female interventional cardiologists.
Heart failure updates focused on home-based care and faster decongestion pathways.
Coronary intervention news emphasized complex PCI, calcified lesions, and robotic assistance.
Postpartum cardiovascular care is moving toward earlier risk detection and system-level follow-up.
Polypill research may broaden from cardiovascular prevention into adjacent chronic disease questions.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Cardiovascular archive on our research hub page

FAQ

What is SCAI studying in WONDER?

SCAI is studying occupational radiation exposure among younger female interventional cardiologists and fellows using surveys and dosimeters. [1]

What did CorFlow report from MOCA II?

CorFlow said phase 1 met safety and performance goals for PCoFI-based MVO diagnosis in STEMI, compared with cardiac MRI. [2]

What is Lasix ONYU?

Lasix ONYU (SQ Innovation) is a subcutaneous furosemide drug-device combination for oedema in adult chronic heart failure. [3]

What did FASTR show for Reprieve Therapy?

Reprieve Cardiovascular said FASTR showed faster decongestion than optimal diuretic therapy, without increased safety events or worsening kidney function. [4]

Where is Shockwave C2 Aero available first?

Johnson & Johnson said Shockwave C2 Aero is available in the US and Japan, with Europe and Canada expected in coming months. [6]

What does the AHA postpartum guidance emphasize?

The AHA guidance emphasizes standardized postpartum systems, interdisciplinary care, policy expansion, and risk factor monitoring. [8]

Entities / Keywords

SCAI, Society for Cardiovascular Angiography and Interventions, WONDER, Women Exposed to Occupational Doses of Radiation
CorFlow Therapeutics, MOCA II, PCoFI, CoFI, microvascular obstruction, MVO, STEMI, cardiac MRI
SQ Innovation, Lasix ONYU, SUBCUT HF II, subcutaneous furosemide, heart failure-associated oedema
Reprieve Cardiovascular, Reprieve Therapy, FASTR, FASTR II, acute decompensated heart failure, ADHF
Robocath, robot-assisted PCI, RA-PCI, next-generation robotic PCI system
Johnson & Johnson, J&J, Shockwave Medical, Shockwave C2 Aero, coronary IVL, calcified coronary artery disease
CardioPharma, CardiaPill, CVD polypill, fixed-dose combination therapy
American Heart Association, AHA, postpartum cardiovascular care, cardio-obstetrics